Search Results

You are looking at 61 - 70 of 336 items for :

  • Refine by Access: All x
Clear All
Full access

Ryan D. Gentzler and Jyoti D. Patel

erlotinib and crizotinib for epidermal growth factor receptor ( EGFR )-mutated and anaplastic lymphoma kinase ( ALK )-rearranged NSCLC, respectively. This article focuses on the first-line treatment of NSCLC with no identifiable mutations with FDA

Full access

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

primary (CK7+, CK20-, TTF1+). The patient's tumor was negative for both KRAS and epidermal growth factor receptor (EGFR)–activating mutations. PET/CT showed the FDG-avid mass in the right upper lobe of the lung, and metastases to the bone, liver, and

Full access

Dung T. Le and Elizabeth M. Jaffee

; DC, dendritic cell; EGFR, epidermal growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulation factor; HER2, human epidermal growth factor receptor-2; IL, interleukin; PD-1, programmed death-1; VEGF, vascular endothelial growth factor

Full access

John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape

rates of epidermal growth factor receptor (EGFR) amplification and chromosome 10 loss. 12 , 16 , 17 Based on an examination of microarray studies from several independent studies, followed by validation in formalin-fixed paraffin-embedded (FFPE) samples

Full access

Suepattra G. May, Caroline Huber, Alison R. Silverstein, Mark Linthicum, Jason Shafrin, Katie Brown, Upal Basu Roy, and Jennifer Bright

Background: Targeted therapies for non-small lung cancer (NSCLC) have vastly improved survival and other outcomes for patients whose tumors have genetic mutations such as ALK, BRAF, EGFR, and ROS1. Identification of genetic mutations often

Full access

Jaideep Sandhu, Chongkai Wang, and Marwan Fakih

, several studies have shown that HER2 amplification is implicated in the resistance to EGFR-targeted therapies. 1 , 4 , 9 , 10 Multiple studies have provided scientific evidence to support HER2-directed therapies in CRC. 3 , 8 These studies interrogated

Full access

Michael P. Douglas, Stacy W. Gray, and Kathryn A. Phillips

policies that addressed single-gene ctDNA testing (eg, EGFR , ALK , BRAF ) that did not include a provision for ctDNA-based panel testing ( supplemental eAppendix 3 ). Private Payers We searched the Canary Insights Database with the terms “liquid biopsy

Full access

Giovanni Palladini and Paolo Milani

, cyclophosphamide/bortezomib/dexamethasone; Dara, daratumumab; DL co , diffusing capacity of the lung for carbon monoxide; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; LMDex, lenalidomide/ melphalan/dexamethasone; NT

Full access

Belqis El Ferjani, Sheenu Chandwani, Meita Hirschmann, Seydeh Dibaj, Emily Roarty, Jianjun Zhang, Waree Rinsurnogkawong, Jeff Lewis, Jack Lee, Jack A. Roth, Stephen Swisher, John V. Heymach, Thomas Burke, and George R. Simon

stage IV diagnosis, 87.2% with nonsquamous histology, 36.1% with bone metastasis, 29.4% with brain metastasis, 43.2% with 0–1 performance status, and 21.6% with a known EGFR or ALK mutation. A total of 233 pts had been tested for PD-L1 (78

Full access

Yvonne Bombard, Peter B. Bach, and Kenneth Offit

recurrence risk within 10 years among node-negative, estrogen receptor-positive patients. 8 , 9 A second example is testing for somatic mutations in the EGFR gene to predict response to tyrosine kinase inhibitors, such as gefitinib in first-line therapy or